General Information
BounceWatch is an independent company data service, not affiliated with Chimeron Bio. To contact Chimeron Bio, visit chimeronbio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Chimeron Bio compare?
A PDF of Chimeron Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Chimeron Bio soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Chimeron Bio on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Chimeron Bio
Business keywords: biotech, synthetic genomics, RNA therapy, personalized gene therapies, cancer treatment, genetic engineering, biomedical technology, precision medicine, pharmaceuticals, innovation, biomedical research, startup, investment, science
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Angel Round | $300.00K | - |
|
24 Dec 2020 |
| Venture Round | Undisclosed | 1 |
Dreavent Capital
|
01 Jan 2018 |
| Seed Round | $845.00K | - |
|
01 Jul 2016 |
Chimeron Bio Alternatives & Competitors
View All AlternativesPersonalized functional genomics transforming the future of cancer
Delivering the next generation gene therapies
A precision oncology company rooted in science and innovation, developing cancer therapies guided by...
FAQ About Chimeron Bio
Source: BounceWatch company record for Chimeron Bio, https://bouncewatch.com/company/chimeron-bio, updated 24 October 2024. When citing, please name BounceWatch and link this page.